Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GTBP GT Biopharma	$2.05 +0.2%	$2.71	$1.72 ▼ $4.10	$6.69M	1.48	286,101 shs	17,528 shs
INKT MiNK Therapeutics	$24.33 +5.3%	$9.85	$4.56 ▼ $76.00	$97.24M	0.19	239,701 shs	1.69 million shs
PASG Passage Bio	$5.86 +5.3%	$7.60	$5.14 ▼ $26.60	$18.56M	1.67	21,154 shs	88,877 shs
SCYX SCYNEXIS	$0.74 -2.2%	$0.81	$0.66 ▼ $2.28	$28.99M	1.57	165,773 shs	185,971 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GTBP GT Biopharma	+2.00%	-4.23%	-27.66%	-10.13%	-28.17%
INKT MiNK Therapeutics	-17.49%	+203.08%	+213.99%	+202.88%	+120.10%
PASG Passage Bio	-6.55%	-36.96%	-30.98%	-15.76%	-70.77%
SCYX SCYNEXIS	0.00%	+9.35%	-3.18%	-15.96%	-65.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GTBP GT Biopharma	2.2306 of 5 stars	3.8	1.0	3.8	0.0	0.6
INKT MiNK Therapeutics	2.5153 of 5 stars	3.2	3.0	2.8	1.7	0.6
PASG Passage Bio	2.5157 of 5 stars	3.5	2.0	1.6	1.7	1.3
SCYX SCYNEXIS	1.0573 of 5 stars	0.0	3.0	3.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GTBP GT Biopharma	3.50	Strong Buy	$11.00	437.90% Upside
INKT MiNK Therapeutics	2.33	Hold	$37.50	54.15% Upside
PASG Passage Bio	3.00	Buy	$150.00	2,461.91% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GTBP, INKT, PASG, and SCYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$35.00
7/11/2025	INKT MiNK Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GTBP GT Biopharma	N/A	N/A	N/A	N/A	($0.75) per share	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($4.94) per share	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	$19.84 per share	N/A
SCYX SCYNEXIS	$3.75M	7.73	N/A	N/A	$1.45 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GTBP GT Biopharma	-$13.16M	-$5.69	N/A	N/A	N/A	N/A	-1,033.08%	-223.20%	8/13/2025 (Estimated)
INKT MiNK Therapeutics	-$9.51M	-$2.52	N/A	N/A	N/A	N/A	N/A	-140.72%	8/12/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$20.40	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)
SCYX SCYNEXIS	-$21.29M	-$0.56	N/A	14.86	N/A	-1,030.04%	-53.47%	-32.86%	8/6/2025 (Estimated)

Latest GTBP, INKT, PASG, and SCYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PASG Passage Bio	-$0.20	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SCYX SCYNEXIS	-$0.23	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	GTBP GT Biopharma	-$0.68	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	INKT MiNK Therapeutics	-$0.45	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	GTBP GT Biopharma	-$0.64	-$0.76	-$0.12	-$0.33	N/A	N/A
5/15/2025	Q1 2025	INKT MiNK Therapeutics	-$0.61	-$0.70	-$0.09	-$0.70	N/A	N/A
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million
5/13/2025	Q1 2025	PASG Passage Bio	-$4.80	-$5.00	-$0.20	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GTBP GT Biopharma	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GTBP GT Biopharma	N/A	0.73	0.73
INKT MiNK Therapeutics	N/A	0.30	0.30
PASG Passage Bio	N/A	3.74	3.74
SCYX SCYNEXIS	N/A	5.83	5.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GTBP GT Biopharma	8.15%
INKT MiNK Therapeutics	2.87%
PASG Passage Bio	53.48%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
GTBP GT Biopharma	3.40%
INKT MiNK Therapeutics	22.48%
PASG Passage Bio	5.00%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GTBP GT Biopharma	8	3.27 million	3.16 million	No Data
INKT MiNK Therapeutics	30	3.99 million	3.09 million	No Data
PASG Passage Bio	130	3.12 million	2.96 million	Optionable
SCYX SCYNEXIS	60	39.02 million	37.12 million	Optionable

GTBP, INKT, PASG, and SCYX Headlines

Recent News About These Companies

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

October 30, 2024 | finance.yahoo.com

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

October 10, 2024 | globenewswire.com

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

October 7, 2024 | finance.yahoo.com

SCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News Summary

October 3, 2024 | benzinga.com

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

October 3, 2024 | globenewswire.com

SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 Shares

September 17, 2024 | insidertrades.com

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

August 27, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP, INKT, PASG, and SCYX Company Descriptions

GT Biopharma NASDAQ:GTBP

$2.04 +0.01 (+0.25%)

As of 02:37 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

MiNK Therapeutics NASDAQ:INKT

$24.33 +1.22 (+5.27%)

As of 02:50 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Passage Bio NASDAQ:PASG

$5.86 +0.30 (+5.31%)

As of 02:45 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

SCYNEXIS NASDAQ:SCYX

$0.74 -0.02 (-2.24%)

As of 02:43 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time